. Author manuscript; available in PMC: 2010 Nov 2.

Published in final edited form as: CNS Neurol Disord Drug Targets. 2010 Nov 1;9(5):661–666. doi: 10.2174/187152710793361595

Table 1. Summary of some agonists and antagonists of VIP-activated receptors.

Some agonistic and antagonistic ligands with the greatest binding affinities to VPAC1, VPAC2, and PAC1 receptors are listed. For a complete overview, see [26].

	VPAC1	VPAC2	PAC1
Agonists	VIP	[125I]BAY 55- 9837	PACAP-38
	PACAP-27	N-stearyl- [Nle17]VIP	PACAP-38
	PACAP-27	Ro25 1553	Maxadilan
	[K15, R16, L17]VIP(3- 7)/GRF(8-27)	Helodermin	Maxadilan
Antagonists	N-stearyl- [Nle17] neurotensin(6- 11)/VIP(7-28)	N-stearyl- Nle17] neurotensin(6- 11)/VIP(7-28	N-stearyl-[Nle17] neurotensin(6-11)/VIP(7-28)
	N-stearyl- [Nle17] neurotensin(6- 11)/VIP(7-28)	N-stearyl- Nle17] neurotensin(6- 11)/VIP(7-28	Max.d.4
	PG 97-269	PG 99-465	PACAP(6-38)
	PG 97-269	PG 97-269	PG 97-269